A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18 and above
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis…The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 6-17
The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury (RE-ENERGIZE)The purpose of this study is to test the following hypotheses:Recruiting Principal Investigator William HendersonBody Locations and Systems Skin ConditionsArea VancouverAge 18 and above
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group study that will investigate the efficacy and safety of mepolizumab SC in adolescent and adult subjects with moderate to severe AD. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 18-70
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3The purpose of this study is to demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD). Recruiting Principal Investigator Sunil KaliaBody Locations and Systems Dermatitis, EczemaArea VancouverAge 18 and above
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic…The purpose of this study is to evaluate the efficacy and safety of two dosage strengths of a new drug (PF-04965842) relative to placebo over 20 weeks of study participation. recruitment poster Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 12 and above
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older…The purpose of this study is to learn about the long-term safety and effectiveness of the study drug, PF-04965842 in participants who previously participated in PF-04965842 AD Phase 3 trials. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 12 and above
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in subjects with unresectable or metastatic melanoma. Closed for Recruitment Principal Investigator Sasha SmiljanicBody Locations and Systems MelanomaArea North VancouverAge 18 and above
Chronic Plaque Psoriasis (Ps) RegistryThe purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps). Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18-99
Psoriasis Longitudinal Assessment and Registry (PSOLAR)The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together).Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18-99
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III…This is an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18 and above
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis. Closed for Recruitment Principal Investigator Youwen ZhouBody Locations and Systems PsoriasisArea VancouverAge 18 and above
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in…This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis. Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18 and above
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis. Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18-99
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in…The purpose of this study is to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 24, to support the use of secukinumab pre-filled syringe (PFS) by subcutaneous (s.c.) self-administration with Closed for Recruitment Principal Investigator Jan P. DutzBody Locations and Systems Psoriasis, Psoriatic ArthritisArea VancouverAge 18 and above
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisTo assess the safety and tolerability of multiple oral doses of BMS-986165 in subjects with moderate to severe psoriasis.Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18-70
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity…The purpose of this study is a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and will include an assessment of 1 or 2 additional doses in two subgroClosed for Recruitment Principal Investigator Jan P. DutzBody Locations and Systems ShinglesArea VancouverAge 50 and above
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006…The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects >= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) anClosed for Recruitment Principal Investigator Jan P. DutzBody Locations and Systems ShinglesArea VancouverAge 50 and above
Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic DermatitisThis is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis (AD) trials. The study primarily evaluates long term safety (adverse events) and immunogenicity.Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 18 and above
Expanded Access Program With Nivolumab to Treat Melanoma (Checkmate 168)The primary purpose of this study is to provide treatment with Nivolumab to subjects with histologically confirmed stage III (unresectable) or stage IV advanced melanoma who have progressed on or after prior treatment with an anti-CTLA4-containing therapy and for subjects with known BRAF mutationClosed for Recruitment Principal Investigator Sasha SmiljanicBody Locations and Systems MelanomaArea VancouverAge 18 and above
